Nasdaq listing awaits Singapore’s US$1.5 billion AI drug-discovery biotech Nanyang Biologics

Its valuation is driven by a proprietary agentic AI platform and potential first-in-class cancer treatment

This is an excerpt. Read the full article at the original source:

Source: businesstimes.com.sg

Your Daily Briefing

Markets, PH news, financial insights, and devotionals — curated by AI and sent at 7 AM PHT. Pick your topics below.

Devotionals

Blog Topics

HR & Workforce

Real Estate & Property

News & Markets